Discrepancies between VEGF-1154 G>A polymorphism analysis performed in peripheral blood samples and FFPE tissue

International Journal of Molecular Sciences

Volumn 15, Issue 8, 2014, Pages 13333-13343

  Marisi, Giorgia ^a   Passardi, Alessandro ^a   Calistri, Daniele ^a   Zoli, Wainer ^a   Amadori, Dino ^a   Ulivi, Paola ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

(mCRC); Formalin fixed paraffin embedded (FFPE) tissue; Growth factor (VEGF); Metastatic colorectal cancer; Peripheral blood; Single nucleotide polymorphisms (SNPs); Vascular endothelial

Indexed keywords

GENOMIC DNA; VASCULOTROPIN; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; VASCULOTROPIN A;

ADULT; AGED; BLOOD SAMPLING; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; ENOS GENE; FEMALE; GENE; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT; VERY ELDERLY; ALLELE; BLOOD; CANCER STAGING; COLORECTAL TUMOR; DNA MICROARRAY; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BASE SEQUENCE; COLORECTAL NEOPLASMS; DNA; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NITRIC OXIDE SYNTHASE TYPE III; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84905281475     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150813333     Document Type: Note

References (27)

1. Kim, J. C.; Ha, Y. J.; Roh, S. A.; Choi, E. Y.; Yoon, Y. S.; Kim, K. P.; Hong, Y. S.; Kim, T. W.; Cho, D. H.; Kim, S. Y.; et al. Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer. Br. J. Cancer 2013, 108, 1862-1869.
2. Schneider, B. P.; Shen, F.; Miller, K. D. Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol. 2012, 13, e427-e436.
3. McWhinney, S. R.; McLeod, H. L. Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics 2009, 10, 489-493.
4. Coura, R.; Prolla, J. C.; Meurer, L.; Ashton-Prolla, P. An alternative protocol for DNA extraction from formalin fixed and paraffin wax embedded tissue. J. Clin. Pathol. 2005, 58, 894-895.
5. Okello, J. B.; Zurek, J.; Devault, A. M.; Kuch, M.; Okwi, A. L.; Sewankambo, N. K.; Bimenya, G. S.; Poinar, D.; Poinar, H. N. Comparison of methods in the recovery of nucleic acids from archival formalin-fixed paraffin-embedded autopsy tissues. Anal. Biochem. 2010, 400, 110-117.
6. Chalkley, R.; Hunter, C. Histone-histone propinquity by aldehyde fixation of chromatin. Proc. Natl. Acad. Sci. USA 1975, 72, 1304-1308.
7. Feldman, M. Y. Reaction of nucleic acids and nucleoproteins with formaldehyde. Prog. Nucleic Acid. Res. Mol. Biol. 1973, 13, 1-49.
8. Lehmann, U.; Kreipe, H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001, 25, 409-418.
9. William, C.; Ponten, F.; Moberg, C.; Soderkvist, P.; Uhlen, M.; Ponten, J.; Sitbon, G.; Lundeberg, J. A high frequency of sequence alteration is due to formalin fixation of archival specimens. Am. J. Pathol. 1999, 155, 1467-1471.
10. Rae, J. M.; Cordero, K. E.; Scheys, J. O.; Lippman, M. E., Flockhart, D. A.; Johnson, M. D. Genotyping for polymorphism drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics 2003, 13, 501-507.
11. Xie, B.; Freudenheim, J. L.; Cumming, S. S.; Singh, B.; He, H.; McCann, S. E.; Moysich, K. B.; Shields, P. G. Accurate genotyping from paraffin-embedded normal tissue adjacent to breast cancer. Carcinogenesis 2006, 27, 307-310.
12. Hagleitner, M. M.; Coenen, M. J.; Jeuken, J. W.; Flucke, U.; Schreuder, H. W.; te Loo, D. M.; Hoogerbrugge, P. M. Taqman genotyping assays can be used on decalcified and paraffin-embedded tissue from patients with osteosarcoma. Pediatr. Blood Cancer 2011, 56, 35-38.
13. Wakatsuki, T.; LaBonte, M. J.; Bohanes, P. O.; Zhang, W.; Yang, D.; Azuma, M.; Barzi, A.; Ning, Y.; Loupakis, F.; Saadat, S.; et al. Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. Mol. Cancer Ther. 2013, 12, 2261-2272.
14. Rae, J. M.; Regan, M. M.; Thibert, J. N.; Gersch, C.; Thomas, D.; Leyland-Jones, B.; Viale, G.; Pusztai, L.; Hayes, D. F.; Skaar, T.; et al. Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J. Natl. Cancer Inst. 2013, 105, 1332-1334.
15. Van Huis-Tanja, L.; Kweekel, D.; Gelderblom, H.; Koopman, M.; Punt, K.; Guchelaar, H. J.; van der Straaten, T. Concordance of genotype for polymorphism in DNA isolated from peripheral blood and colorectal cancer tumor samples. Pharmacogenomics 2013, 14, 2005-2012.
16. Baak-Pablo, R.; Dezentje, V.; Guchelaar, H. J.; van der Straaten, T. Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. J. Mol. Diagn. 2010, 12, 746-749.
17. Koutras, A. K.; Antonacopoulou, A. G.; Eleftheraki, A. G.; Dimitrakopoulos, F. I.; Koumarianou, A.; Varthalitis, I.; Fostira, F.; Sgouros, J.; Briasoulis, E.; Bournakis, E.; et al. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J. 2012, 12, 468-475.
18. Hansen, T. F.; Christensen, R. D.; Andersen, R. F.; Spindler, K. L. G.; Johnsson, A.; Jakobsen, A. The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemiotherapy in patients with metastatic colorectal cancer. Int. J. Colorectal Dis. 2011, 27, 715-720.
19. Jin, Q.; Hemminki, K.; Enquist, K.; Lenner, P.; Grzybowska, E.; Klaes, R.; Henriksson, R.; Chen, B.; Pamula, J.; Pekala, W.; et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin. Cancer Res. 2005, 11, 3647-3653.
20. Jacobs, E. J.; Feigelson, H. S.; Bain, E. B.; Brady, K. A.; Rodriguez, C.; Stevens, V. L.; Patel, A. V.; Thun, M. J.; Calle, E. E. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006, 8, doi: 10. 1186/bcr1400.
21. Dassoulas, K.; Gazouli, M.; Rizos, S.; Theodoropoulos, G.; Christoni, Z., Nikiteas, N.; Karakitsos, P. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol. Carcinog. 2009, 48, 563-569.
22. Gilbert, M. T.; Haselkorn, T.; Bunce, M.; Sanchez, J. J.; Lucas, S. B.; Jewell, L. D.; van Marck, E.; Worobey, M. The isolation of nucleic acid from fixed, paraffin-embedded tissues-which methods are useful when? PLoS One 2007, 2, e537.
23. Lasko, D.; Cavenee, W.; Nordenskjöld, M. Loss of constitutional heterozygosity in human cancer. Annu. Rev. Genet. 1991, 25, 281-314.
24. Regan, M. M.; Leyland-Jones, B.; Bouzyk, M.; Pagani, O.; Tang, W.; Kammler, R.; dell'Orto, P.; Biasi, M. O.; Thürlimann, B.; Lyng, M. B.; et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial. J. Natl. Cancer Inst. 2012, 104, 441-451.
25. Huijsmans, C. J.; Damen, J.; van der Linden, J. C.; Savelkoul, P. H.; Hermans, M. H. Comparative analysis of four methods to extract DNA from paraffin-embedded tissues: Effect on downstream molecular applications. BMC Res. Notes 2010, 3, doi: 10. 1186/1756-0500-3-239.
26. Nakamura, Y.; Ratain, M. J.; Cox, N. J.; McLeod, H. L.; Kroetz, D. L.; Flockhart, D. A. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 trial. J. Natl. Cancer Inst. 2012, 104, doi: 10. 1093/jnci/djs304.
27. Passardi, A.; Nanni, O.; Tassinari, D.; Turci, D.; Cavanna, L.; Fontana, A.; Ruscelli, S.; Mucciarini, C.; Lorusso, V.; Ragazzini, A.; et al. Effectiveness of bevacizumab added to gold standard chemotherapy in metastatic colorectal cancer: Final results for first-line treatment from the ITACA randomized clinical trial. J. Clin. Oncol. 2014, in press.